London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Because it was front run from 75p by someone who got wind of the news...
Good news, guess it has to settle somewhere. I'm not selling any of mine.
GLA
Got it.Just read the RNS.
Thanks Hunsen.So is Efmody then Chroncort? Never seen it referred to as that.Not that I'm complaining.
£1 already there 98 on the ask
£2-3 plus incoming here
No brainer
RNS? L2" flooded with buys
Will it rise over £1 when RNS follows?
www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021
Approved already
This says one orphan drug approved?
https://mobile.twitter.com/EMA_News
Something just happened some call a plumber
Think approval has been done. News leaked.
Quick move to 81p on the bid
No way this will fail gla
Oh, I forgot the link to the LTIP, see for yourself;
https://otp.tools.investis.com/clients/uk/diurnal_limited/rns/regulatory-story.aspx?cid=1282&newsid=1439666
Just a friendly reminder for long term holders and a heads up to new investors. The DNL Management Team are well motivated by a LTIP which will reward them with £1m + in shares providing the business growth and development criteria are met. This includes;
· Achieving a target share price of 100 pence for a three-month rolling period during the five years following grant
· Confirmation from the US FDA of progression of DITEST™ to Phase 3 development
· Global Alkindi® and Chronocort® sales for the year ended 30 June 2023 in line with Company forecasts
· Submission of Marketing Authorisation Application in Japan for Alkindi® or a Japanese partner in place
· Chronocort® approved in adrenal insufficiency (AI) in at least one major global territory
When everything on this list is achieved, a £1 share price will be a distant memory.
IMO, this share will go a long way.
Here's what they've previously stated...
"In parallel with the regulatory discussions, the Company is assessing the opportunity to fund the US Phase 3 development itself in order to increase the future value of the programme, as well as significantly broadening the pool of potential commercialisation partners."
Promising.
Are they not partnering with Eton on chronocort in the US?
If not I imagine a partner will be announced not long after ema approval.
As confidence builds for European approval worth reminding ourselves of the outlook statement in the Feb interims...
Outlook
If approved by the EMA, Chronocort® will provide the Company's commercial cortisol replacement therapy franchise with critical mass, enabling Diurnal to build a strong and profitable European business through penetration of the combined addressable market for the treatment of CAH and paediatric AI, which is estimated by the Company to be worth c.$300 million in Europe alone. In addition, the Group expects an increased contribution from its licensing and distribution partners outside of Europe once regulatory and/or pricing and reimbursement activities for Alkindi® are completed in these territories.
In the US, Diurnal continues to assess the optimal timing for seeking a partner for the commercialisation of Chronocort, which may be following the completion of Phase 3 development itself: if successful, this would be expected to markedly increase the value of the asset.
DITEST™ represents a further valuable addition to Diurnal's growing pipeline of novel endocrinology treatments and, following the fundraising in October 2020, the Company will move forward with the next stage of development in order to maximise the value of this product in the $4.8bn potential market in the US and Europe.
Breaking out
Is active
HI dave imo dnl has approval and i doubt it been put off as no rns to say so .PRICE ACTION could hit 1,25
Not priced in. The NPV of the cashflows that could be generated from DNL’s first two products has changed from £389m to £455m. Risk-adjustment to take account of the different stages of development in different territories reduces this to £298m, or 344p per share.
This should be 344p upon approval
ON news i can see a lot of sellers the traders
On approval i feel a pound been a nice ride this week atb everyone will chill now